APLM
Price
$18.52
Change
+$0.53 (+2.95%)
Updated
Dec 26, 12:09 PM (EDT)
Capitalization
38.56M
Intraday BUY SELL Signals
PHAR
Price
$18.09
Change
+$0.85 (+4.93%)
Updated
Dec 24 closing price
Capitalization
1.18B
76 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APLM vs PHAR

Header iconAPLM vs PHAR Comparison
Open Charts APLM vs PHARBanner chart's image
Apollomics
Price$18.52
Change+$0.53 (+2.95%)
Volume$2.03K
Capitalization38.56M
Pharming Group
Price$18.09
Change+$0.85 (+4.93%)
Volume$15.7K
Capitalization1.18B
APLM vs PHAR Comparison Chart in %
APLM
Daily Signal:
Gain/Loss:
PHAR
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
APLM vs. PHAR commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLM is a Buy and PHAR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (APLM: $17.99 vs. PHAR: $18.09)
Brand notoriety: APLM and PHAR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLM: 80% vs. PHAR: 78%
Market capitalization -- APLM: $38.56M vs. PHAR: $1.18B
APLM [@Biotechnology] is valued at $38.56M. PHAR’s [@Biotechnology] market capitalization is $1.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLM’s FA Score shows that 0 FA rating(s) are green whilePHAR’s FA Score has 1 green FA rating(s).

  • APLM’s FA Score: 0 green, 5 red.
  • PHAR’s FA Score: 1 green, 4 red.
According to our system of comparison, both APLM and PHAR are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLM’s TA Score shows that 4 TA indicator(s) are bullish while PHAR’s TA Score has 4 bullish TA indicator(s).

  • APLM’s TA Score: 4 bullish, 2 bearish.
  • PHAR’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, both APLM and PHAR are a good buy in the short-term.

Price Growth

APLM (@Biotechnology) experienced а +19.30% price change this week, while PHAR (@Biotechnology) price change was +8.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

PHAR is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHAR($1.18B) has a higher market cap than APLM($38.6M). APLM YTD gains are higher at: 84.513 vs. PHAR (79.732). PHAR has higher annual earnings (EBITDA): 44.7M vs. APLM (-56.38M). APLM has less debt than PHAR: APLM (4.72M) vs PHAR (131M). PHAR has higher revenues than APLM: PHAR (362M) vs APLM (0).
APLMPHARAPLM / PHAR
Capitalization38.6M1.18B3%
EBITDA-56.38M44.7M-126%
Gain YTD84.51379.732106%
P/E RatioN/AN/A-
Revenue0362M-
Total CashN/A166M-
Total Debt4.72M131M4%
TECHNICAL ANALYSIS
Technical Analysis
APLMPHAR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
57%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 3 days ago
72%
MACD
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 3 days ago
61%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
51%
Bullish Trend 3 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
45%
Bullish Trend 3 days ago
71%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 5 days ago
69%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 24 days ago
82%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
APLM
Daily Signal:
Gain/Loss:
PHAR
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CELU1.320.03
+2.33%
Celularity
LRCX177.332.17
+1.24%
Lam Research Corp
BTSG37.73-0.05
-0.13%
BrightSpring Health Services
MBX32.11-0.09
-0.28%
MBX Biosciences Inc.
FNLC26.92-0.11
-0.41%
First Bancorp

APLM and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLM has been loosely correlated with SNTI. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if APLM jumps, then SNTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLM
1D Price
Change %
APLM100%
+4.41%
SNTI - APLM
47%
Loosely correlated
-0.86%
MGX - APLM
37%
Loosely correlated
+1.16%
IPHA - APLM
36%
Loosely correlated
-3.41%
PRAX - APLM
35%
Loosely correlated
-0.35%
QSI - APLM
34%
Loosely correlated
+6.50%
More

PHAR and

Correlation & Price change

A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAR
1D Price
Change %
PHAR100%
+4.93%
APLM - PHAR
31%
Poorly correlated
+4.41%
ANTX - PHAR
29%
Poorly correlated
+1.79%
ADPT - PHAR
27%
Poorly correlated
-0.42%
IBRX - PHAR
27%
Poorly correlated
+1.90%
ATXS - PHAR
26%
Poorly correlated
+0.62%
More